Because research in regard to biochemical mechanisms involved in CFS is lacking, further investigation is needed, such as a possible link to the biochemical mechanism of C-1 esterase inhibitor.
Studies of C-1 esterase inhibitor deficiency focused on angioedema with specific mention of mechanisms involved in hereditary and acquired angio-neurotic edema. C-1 esterase inhibitor consists of a single polypeptide chain of 478 amino acid residues. C-1 INH deficiency results in increased vasoactive substance release and vascular permeability as well as recurrent mast cell degranulation. A study is needed to determine if this mechanism is involved in CFS.
The purpose of this study is to compare CFS and non-CFS women in regard to C-1 esterase inhibitor levels, fatigue, depression, and activities of daily living (ADL).
The study questions that will be investigated are listed below.
1. What is the difference in C-1 esterase inhibitor levels in CFS patients and non-CFS patients?
2. How do CFS patients' scores on the Fatigue Scale differ from non-CFS patients' scores?
3. How do CFS patients' scores on the Beck Depression Scale differ from non-CFS patients' scores?
4. How do CFS patients' scores on the ADL's index differ from non-CFS patients' scores?
CSF patients∆ C-1 esterase inhibitor levels will differ significantly from non-CFS patients.
CSF patients∆ scores on the Fatigue Scale will differ significantly from non-CFS patients.
CSF patients∆ scores on the Beck Depression Scale will differ significantly from non-CFS patients.
CSF patients∆ scores on the ADL index will differ significantly from non-CFS patients.
The following terms are defined for this study.
For the purposes of this study CFS is defined as a clinical condition which is characterized by severe and disabling fatigue and depression, and affects activities of daily living.
C-1 esterase inhibitor is defined as a plasma, alpha 2-glycopr...
Chronic Fatique Syndrome. (1969, December 31). In LotsofEssays.com. Retrieved 18:08, August 25, 2016, from http://www.collegetermpapers.com/viewpaper/1304224101.html